{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:33:32Z","timestamp":1792816412461,"version":"4.5.0"},"reference-count":25,"publisher":"American Society of Hematology","issue":"23","license":[{"start":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T00:00:00Z","timestamp":1721692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,10]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>We hypothesized that the inferior disease-free survival (DFS) seen in older patients who underwent \u03b1\u03b2-T-cell\/CD19\u2013depleted (AB-TCD) haploidentical hematopoietic cell transplantation (HCT) for hematologic malignancies is caused by excessive exposure to rabbit antithymocyte globulin (rATG; Thymoglobulin). Between 2015 and 2023, 163 patients with a median age of 13 years (range, 0.4-27.4) underwent AB-TCD haploidentical HCT for the treatment of acute lymphoblastic leukemia (n = 98), acute myeloid leukemia\/myelodysplastic syndrome (n = 49), or other malignancies (n = 16) at 9 centers in 2 prospective trials. Exposures to rATG before and after HCT were predicted using a validated pharmacokinetic model. Receiver operating characteristic curves were used to identify the optimal target windows for rATG exposure in terms of outcomes. We identified 4 quadrants of rATG exposure, namely quadrant 1 (n = 52) with a high pre-HCT area under curve (AUC; \u226550 arbitrary units [AU] per day per milliliter) and a low post-HCT AUC (&amp;lt;12 AU per day per liter); quadrant 2 (n = 47) with a low pre- and post-HCT AUC; quadrant 3 (n = 13) with a low pre-HCT and a high post-HCT AUC; and quadrant 4 (n = 51) with a high pre- and post-HCT AUC. Quadrant 1 had a 3-year DFS of 86.5%, quadrant 2 had a DFS of 64.6%, quadrant 3 had a DFS of 32.9%, and for quadrant 4 it was 48.2%. An adjusted regression analysis demonstrated additional factors that were associated with an increased hazard for worse DFS, namely minimal residual disease (MRD) positivity and cytomegalovirus (CMV) R+\/D\u2212 serostatus. Nonoptimal rATG exposure exhibited the strongest effect in unadjusted and adjusted (MRD status or CMV serostatus) analyses. High exposure to rATG after HCT was associated with inferior DFS following AB-TCD haploidentical HCT for pediatric patients with hematologic malignancies. Model-based dosing of rATG to achieve optimal exposure may improve DFS. These trials were registered at www.ClinicalTrials.gov as #NCT02646839 and #NCT04337515.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024012670","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T21:02:05Z","timestamp":1721768525000},"page":"6003-6014","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["Effect of rabbit ATG PK on outcomes after TCR-\u03b1\u03b2\/CD19\u2013depleted pediatric haploidentical HCT for hematologic malignancy"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6146-3952","authenticated-orcid":false,"given":"Christopher C.","family":"Dvorak","sequence":"first","affiliation":[{"name":"1Division of Pediatric Allergy, Immunology, and Bone Marrow Transplantation, Department of Clinical Pharmacy, University of California San Francisco Benioff Children\u2019s Hospitals, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janel R.","family":"Long-Boyle","sequence":"additional","affiliation":[{"name":"1Division of Pediatric Allergy, Immunology, and Bone Marrow Transplantation, Department of Clinical Pharmacy, University of California San Francisco Benioff Children\u2019s Hospitals, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Holbrook-Brown","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Oncology, Section of Transplantation Intermountain Primary Children\u2019s Hospital, Huntsman Cancer Institute, Spencer Fox Eccles School of Medicine at The University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisham","family":"Abdel-Azim","sequence":"additional","affiliation":[{"name":"3Cancer Center, Children\u2019s Hospital and Medical Center, Loma Linda University School of Medicine, Loma Linda, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3729-436X","authenticated-orcid":false,"given":"Alice","family":"Bertaina","sequence":"additional","affiliation":[{"name":"4Division of Pediatric Hematology, Oncology, Stem Cell Transplantation & Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2993-0490","authenticated-orcid":false,"given":"Anant","family":"Vatsayan","sequence":"additional","affiliation":[{"name":"5Division of Blood and Marrow Transplantation, Children\u2019s National Hospital, George Washington University School of Medicine and Health Sciences, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie-An","family":"Talano","sequence":"additional","affiliation":[{"name":"6Division of Pediatric Hematology, Oncology, and Blood and Marrow Transplant, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6210-2262","authenticated-orcid":false,"given":"Nancy","family":"Bunin","sequence":"additional","affiliation":[{"name":"7Division of Oncology, Children\u2019s Hospital of Philadelphia, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3665-3102","authenticated-orcid":false,"given":"Eric","family":"Anderson","sequence":"additional","affiliation":[{"name":"8Division of Pediatric Hematology-Oncology, Rady Children\u2019s Hospital, University of California San Diego, San Diego, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allyson","family":"Flower","sequence":"additional","affiliation":[{"name":"9Division of Pediatric Hematology, Oncology, and Stem Cell Transplantation, New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nahal","family":"Lalefar","sequence":"additional","affiliation":[{"name":"10Division of Hematology, University of California San Francisco Benioff Children\u2019s Hospitals, Oakland, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine S.","family":"Higham","sequence":"additional","affiliation":[{"name":"1Division of Pediatric Allergy, Immunology, and Bone Marrow Transplantation, Department of Clinical Pharmacy, University of California San Francisco Benioff Children\u2019s Hospitals, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neena","family":"Kapoor","sequence":"additional","affiliation":[{"name":"11Division of Pediatric Hematology, Oncology, and Transplantation and Cellular Therapy, University of Southern California Children\u2019s Hospital Los Angeles, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orly","family":"Klein","sequence":"additional","affiliation":[{"name":"4Division of Pediatric Hematology, Oncology, Stem Cell Transplantation & Regenerative Medicine, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryanne C.","family":"Odinakachukwu","sequence":"additional","affiliation":[{"name":"5Division of Blood and Marrow Transplantation, Children\u2019s National Hospital, George Washington University School of Medicine and Health Sciences, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6160-2791","authenticated-orcid":false,"given":"Soohee","family":"Cho","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Oncology, Section of Transplantation Intermountain Primary Children\u2019s Hospital, Huntsman Cancer Institute, Spencer Fox Eccles School of Medicine at The University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Jacobsohn","sequence":"additional","affiliation":[{"name":"5Division of Blood and Marrow Transplantation, Children\u2019s National Hospital, George Washington University School of Medicine and Health Sciences, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1091-2567","authenticated-orcid":false,"given":"Willem","family":"Collier","sequence":"additional","affiliation":[{"name":"12Division of Biostatistics, Department of Population and Public Health Sciences, University of Southern California, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3030-8420","authenticated-orcid":false,"given":"Michael A.","family":"Pulsipher","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Oncology, Section of Transplantation Intermountain Primary Children\u2019s Hospital, Huntsman Cancer Institute, Spencer Fox Eccles School of Medicine at The University of Utah, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,11,27]]},"reference":[{"issue":"4","key":"2024121014362099900_bib1","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"1-2","key":"2024121014362099900_bib2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.imlet.2013.09.027","article-title":"Negative depletion of \u03b1\/\u03b2+ T cells and of CD19+ B lymphocytes: a novel frontier to optimize the effect of innate immunity in HLA-mismatched hematopoietic stem cell transplantation","volume":"155","author":"Locatelli","year":"2013","journal-title":"Immunol Lett"},{"issue":"5","key":"2024121014362099900_bib3","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1182\/blood-2014-03-563817","article-title":"HLA-haploidentical stem cell transplantation after removal of \u03b1\u03b2+ T and B cells in children with nonmalignant disorders","volume":"124","author":"Bertaina","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2024121014362099900_bib4","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood-2017-04-779769","article-title":"Outcome of children with acute leukemia given HLA-haploidentical HSCT after \u03b1\u03b2 T-cell and B-cell depletion","volume":"130","author":"Locatelli","year":"2017","journal-title":"Blood"},{"issue":"4","key":"2024121014362099900_bib5","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/j.jaci.2017.07.008","article-title":"T-cell receptor \u03b1\u03b2+ and CD19+ cell-depleted haploidentical and mismatched hematopoietic stem cell transplantation in primary immune deficiency","volume":"141","author":"Shah","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"24","key":"2024121014362099900_bib6","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1182\/blood.2022015959","article-title":"KIR-favorable TCR-\u03b1\u03b2\/CD19-depleted haploidentical HCT in children with ALL\/AML\/MDS: primary analysis of PTCTC ONC1401","volume":"140","author":"Pulsipher","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2024121014362099900_bib7","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S2352-3026(17)30029-7","article-title":"Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis","volume":"4","author":"Admiraal","year":"2017","journal-title":"Lancet Haematol"},{"issue":"23","key":"2024121014362099900_bib8","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1182\/blood-2016-06-721936","article-title":"Excellent T-cell reconstitution and survival depend on low ATG exposure after pediatric cord blood transplantation","volume":"128","author":"Admiraal","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2024121014362099900_bib9","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1182\/bloodadvances.2021005584","article-title":"Antithymocyte globulin exposure in CD34+ T-cell-depleted allogeneic hematopoietic cell transplantation","volume":"6","author":"Lakkaraja","year":"2022","journal-title":"Blood Adv"},{"issue":"6","key":"2024121014362099900_bib10","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.jcyt.2024.02.015","article-title":"High-dose individualized antithymocyte globulin with therapeutic drug monitoring in high-risk cord blood transplant","volume":"26","author":"Admiraal","year":"2024","journal-title":"Cytotherapy"},{"issue":"2","key":"2024121014362099900_bib11","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1016\/S2352-3026(21)00375-6","article-title":"Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial","volume":"9","author":"Admiraal","year":"2022","journal-title":"Lancet Haematol"},{"issue":"10","key":"2024121014362099900_bib12","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.bbmt.2017.06.021","article-title":"Pharmacokinetics and model-based dosing to optimize fludarabine therapy in pediatric hematopoietic cell transplant recipients","volume":"23","author":"Ivaturi","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"14","key":"2024121014362099900_bib13","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1182\/bloodadvances.2018029421","article-title":"Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes","volume":"3","author":"Langenhorst","year":"2019","journal-title":"Blood Adv"},{"issue":"11","key":"2024121014362099900_bib14","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.3390\/pharmaceutics14112462","article-title":"Prospective validation and refinement of a population pharmacokinetic model of fludarabine in children and young adults undergoing hematopoietic cell transplantation","volume":"14","author":"Brooks","year":"2022","journal-title":"Pharmaceutics"},{"issue":"22","key":"2024121014362099900_bib15","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/blood-2014-12-615757","article-title":"IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients","volume":"125","author":"Pulsipher","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2024121014362099900_bib16","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2024121014362099900_bib17","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2024121014362099900_bib18","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2352-3026(15)00045-9","article-title":"Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis","volume":"2","author":"Admiraal","year":"2015","journal-title":"Lancet Haematol"},{"key":"2024121014362099900_bib19","doi-asserted-by":"crossref","first-page":"38","DOI":"10.21037\/sci.2017.05.02","article-title":"Immune reconstitution and outcomes after conditioning with anti-thymocyte-globulin in unrelated cord blood transplantation; the good, the bad, and the ugly","volume":"4","author":"de Koning","year":"2017","journal-title":"Stem Cell Investig"},{"issue":"9","key":"2024121014362099900_bib20","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/bloodadvances.2018030247","article-title":"Antirelapse effect of pretransplant exposure to rabbit antithymocyte globulin","volume":"3","author":"Dabas","year":"2019","journal-title":"Blood Adv"},{"issue":"1","key":"2024121014362099900_bib21","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1182\/bloodadvances.2019000836","article-title":"Robust CD4+ T-cell recovery in adults transplanted with cord blood and no antithymocyte globulin","volume":"4","author":"Politikos","year":"2020","journal-title":"Blood Adv"},{"issue":"24","key":"2024121014362099900_bib22","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1182\/bloodadvances.2017010827","article-title":"Cord blood transplantation recapitulates fetal ontogeny with a distinct molecular signature that supports CD4+ T-cell reconstitution","volume":"1","author":"Hiwarkar","year":"2017","journal-title":"Blood Adv"},{"issue":"4","key":"2024121014362099900_bib23","doi-asserted-by":"crossref","first-page":"330.e1","DOI":"10.1016\/j.jtct.2021.01.010","article-title":"Serotherapy-free regimen improves non-relapse mortality and immune recovery among the recipients of \u03b1\u03b2 TCell-depleted haploidentical grafts: retrospective study in childhood leukemia","volume":"27","author":"Shelikhova","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"2024121014362099900_bib24","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3389\/fimmu.2019.00315","article-title":"Differential elimination of anti-thymocyte globulin of fresenius and genzyme impacts T-cell reconstitution after hematopoietic stem cell transplantation","volume":"10","author":"Oostenbrink","year":"2019","journal-title":"Front Immunol"},{"issue":"5","key":"2024121014362099900_bib25","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1182\/bloodadvances.2017015487","article-title":"Filgrastim enhances T-cell clearance by antithymocyte globulin exposure after unrelated cord blood transplantation","volume":"2","author":"de Koning","year":"2018","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/23\/6003\/2344979\/blooda_adv-2024-012670-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/23\/6003\/2344979\/blooda_adv-2024-012670-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T14:38:00Z","timestamp":1733841480000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/23\/6003\/517130\/Effect-of-rabbit-ATG-PK-on-outcomes-after-TCR-CD19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,27]]},"references-count":25,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2024,12,10]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024012670","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,27]]}}}